Epigenetic changes can switch viral latency to lytic replication (12, –, 15), and therefore histone deacetylase (HDAC) inhibitors have been used to induce KSHV reactivation (16) and have been considered a potential anticancer therapeutic option to treat PEL (17, 18). Here, HDAC9 is linked to primary effusion lymphoma.